OXYTOCIN BIO 5 IU/ml injection solution
|type of preparative:||Hormones|
|target species animals:||Sheep, Pig, Horse, Goat, Dog, Cattle|
1 ml of the product contains:
Oxytocinum 5.0 IU
Excipients: chlorobutanol hemihydrate 4.0 mg
To support delivery in case of primary and secondary depression of contractions and to accelerate the expulsive phase of delivery.
During the puerperal period: depression of uterine muscle contractility: To stimulate involution in case of placenta retention and exometra (the product is administered immediately after delivery or caesarotomy and two to four hours later), to remove the pathological contents of uterus, endometritis, pyometra.
Agalaxia in consequence of milk production disorder in all target species. To remove residual milk and toxic material from the udder after delivery and during the treatment of infectious mastitis in cows.
Do not use for complicated deliveries (too big foetus, foetus abnormal position, torsio uteri etc.). Do not use at insufficient release of cervix in case of pyometra.
Do not use in case of uterine muscle hypertension.
Hypercontractions, uterine spasms or rupture in case of overdose.
High doses of oxytocin may cause uterine spasms which may result, especially in pigs, in a longer litter, increased hypoxia of born piglets and reduced number of live-born piglets.
Cows, mares, sheep, goats, sows, bitches.
Uterus inaction, milk ejection, mastitis, uterus involution: 20 – 40 IU (i.m. or s.c.), 2.5 – 10 IU (i.v.).
- Uterus inaction: 20 – 40 IU (i.m. or s.c.), 2.5 – 10 IU (i.v.).
- Placenta retention: 10 – 20 IU (i.m. or s.c.).
- Milk ejection, uterus involution: 40 IU (i.m. or s.c.), 10 IU (i.v.)
- Uterus inaction: 10 IU (i.m. or s.c.), 0.5 – 2.5 IU (i.v.).
- Milk ejection, uterus involution: 10 – 20 IU (i.m. or s.c.), 0.5 – 2.5 IU (i.v.).
- Uterus inaction, uterus involution, placenta retention, milk ejection: 10 – 30 IU (i.m. or s.c.),
- 0.5 – 2.5 IU (i.v.).
- Uterus inaction, uterus involution, placenta retention, milk ejection 2 – 10 IU (i.m. or s.c.),
- 0.5 IU (i.v.)
Advice on correct administration:
The product may be applied intramuscularly (i.m.), subcutaneously (s.c.) or intravenously (i.v.). For the intravenous infusion the product may be diluted with physiological solution or 5% glucose solution.
In obstetric indications, a slow intravenous, subcutaneous or intramuscular application is possible. Repeated administration of small doses is preferred to one big dose. In sheep, the intramuscular application should be preferred.
The slow intravenous application is used to produce ejection of residual milk and retained placenta. For the intravenous application of small doses the respective product should be diluted in a higher amount of physiological solution.
If oxytocin is used for the management of delivery, it is necessary to verify that the cervix is dilated in order to prevent the death of foetus or a possible rupture of uterus.
Special storage precautions:
Keep out of the reach and sight of children. Store in a refrigerator (2 °C – 8 °C).
Protect from frost. Do not use after the expiry date stated on the label.
The treated animals should not be stressed as epinephrine released during stress may reduce the oxytocin effect. Exogenic oxytocin is not recommended as a control tool to increase the milk production.
This product should be administered while observing the general principles of hygiene and good clinical practice.
The injected product should be administered carefully to prevent accidental self-injury. In case of accidental self-administration seek medical attention immediately and show the package leaflet or the label to your physician.
Pregnant women should avoid handling with this veterinary medicinal product.
Interaction with other medicinal products and other forms of interaction:
Oxytocin is not efficient if administered shortly after beta2-adrenergic agonists. Prostaglandine F2alpha and oxytocin strengthen mutually their effects on the uterus.
Oxytocin is a natural nonapeptide released from the posterior lobe of hypophysis. Oxytocin shows uterotonic activity and supports the ejection of milk. The stimulation of uterine muscle during delivery is of particular physiological importance. This stimulation is enabled by activating of MAP (mitogen activating protein) kinase through the medium of G protein of myometrium cells. Oxytocin stimulates releasing of prostaglandin E2 by amnion cells, which also plays an important part in initiating of delivery.
Moreover, oxytocin stimulates intensively the secretion of prostaglandin PGF2α by endometrium cells, which produces luteolysis in non-pregnant animals. This oxytocin effect is mediated by its bonding to membrane receptors and by activating of phospholipase C, which leads to activating of intracellular cascade by the reaction which mobilizes arachidonic acid from membrane phospholipides. The mobilized arachidonic acid is oxygenized to prostaglandin PGH2 through the medium of prostaglandin H2 endoperoxide synthetase PGHS-2 and is converted to PGF2α by PGF synthetase. Oxytocin increases the concentration of PGHS-2 mRNA, which influences the secretion of PGF2α. This prostaglandin, similarly to prostaglandin E2, influences the contractility of myometrium.
At the intravenous application the onset of oxytocin effect is very fast in all target species (in 20 – 30 seconds) and the time of effect is short (5 – 10 minutes). The half-life is about 20 minutes in dependence on the treated species.
At the intramuscular or subcutaneous application the onset of oxytocin effect is between 5 and 10 minutes and the time of effect is between 20 and 30 minutes. The efficacy decreases in the course of following 20 minutes.
In case of milk ejection stimulation the onset of oxytocin effect is quite fast and ¾ of the udder volume are ejected on average in 3 minutes after the application.
The shelf life of the veterinary medicinal product in intact package is 2 years.
Shelf-life after first opening the container is 28 days.
+420 517 318 598